PLEDPHARMA AB (PUBL) Inactive Instrument
PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
| Sales 2024 * | 61.02M 5.76M | Sales 2025 * | 491M 46.35M | Capitalization | 1.61B 152M |
|---|---|---|---|---|---|
| Net income 2024 * | -293M -27.64M | Net income 2025 * | 107M 10.09M | EV / Sales 2024 * | 24.7 x |
| Net cash position 2024 * | 105M 9.86M | Net cash position 2025 * | 229M 21.56M | EV / Sales 2025 * | 2.81 x |
| P/E ratio 2024 * |
-5.39
x | P/E ratio 2025 * |
12.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on PledPharma AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
| Chief Tech/Sci/R&D Officer | - | 22-05-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 21-03-31 |
| Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 21-03-31 |
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +16.49% | 122B | |
| +21.73% | 115B | |
| +21.92% | 26.64B | |
| -21.81% | 19.91B | |
| -16.80% | 16.32B | |
| -44.74% | 15.52B | |
| -18.81% | 15.49B | |
| +62.72% | 14.83B | |
| +3.09% | 13.67B |
